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Abstract
Background: Chorea in Huntington's Disease (HD) is usually treated with antidopaminergic
neuroleptics like haloperidol, olanzapine and tiaprid or dopamine depleting drugs like
tetrabenazine. Some patients with hyperkinesia, however, react to treatment with
antidopaminergic drugs by developing extrapyramidal side effects. In earlier studies valproic acid
showed no beneficial effect on involuntary choreatic movements. Myoclonus is rare in HD and is
often overseen or misdiagnosed as chorea.
Methods:  In this report, we present eight patients whose main symptom is myoclonic
hyperkinesia. All patients were treated with valproic acid and scored by using the Unified
Huntington's Disease Rating Scale (UHDRS) motor score before and after treatment. In addition
to this, two patients agreed to be videotaped.
Results: In seven patients myoclonus and, therefore the UHDRS motor score improved in a dose
dependent manner. In three of these patients antidopaminergic medication could be reduced.
Conclusion: In the rare subgroup of HD patients suffering from myoclonic hyperkinesia, valproic
acid is a possible alternative treatment.
Background
Huntington's disease (HD) is an autosomal dominantly
transmitted neurodegenerative disorder based on expan-
sions of translated CAG repeats in the huntingtin gene
beyond a threshold of 36 to >200 units. The characteristic
motor feature of HD is chorea, but parkinsonism and
involuntary movements such as dystonia and myoclonus
can also be present. Choreatic movements are usually
treated with antidopaminergic neuroleptics like haloperi-
dol, fluphenazine, olanzapine or tiaprid and alternatively,
dopamine-depleting drugs like tetrabenazine. Dopamin-
ergic drugs or even low-dose levodopa can be adminis-
tered in patients with the juvenile akinetic rigid variant of
HD.
Myoclonus is a rare feature of HD. It does not sufficiently
respond to antidopaminergic medication. A few reports of
myoclonus in HD have mainly concerned cases of juve-
nile onset [1-3].
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Earlier studies using valproic acid in HD did not show a
beneficial effect on involuntary movements particularly
with regard to choreatic hyperkinesias ([4] 2 patients;
[5,6] 5 patients; [7] 14 patients; [8] 8 patients; [9] 3
patients; [10] 1 patient).
On the other hand, a few case reports describing myo-
clonus in HD report an improvement in movement dis-
turbances after administration of valproic acid or a
medication other than antidopaminergics. Carella et al.
described a patient with adult-onset HD suffering from
prominent action myoclonus. In this case, treatment with
valproic acid greatly reduced myoclonus, suggesting that
the gamma-aminobutyric acid (GABA) system might be
involved in the pathophysiology of myoclonus in HD
[11]. Another case report refers to two brothers with clin-
ically diagnosed adult HD. Years after their first symptoms
appeared, they developed disabling myoclonus, which
could be brought under control by administration of val-
proic acid [12]. Thompson et al. describe three patients
with HD who developed symptoms before the age of 30
with myoclonus as the predominant feature. The myo-
clonus improved under piracetam therapy in one patient
and a combination of valproic acid and clonazepam in
the others [13]. Kereshi et al. described a reduction of
symptoms in a 26 year old woman suffering from HD
with myoclonic hyperkinesias after a combined treatment
with haloperidol and valproic acid [14]. Two further case
reports describe an improvement of severe intention myo-
clonus by use of clonazepam in adult HD [15,1].
Funakawa et al. report on a cortical reflex myoclonus in
Table 2: Clinical data and co-medication before and after treatment
Patient Initial 
UHDRS 
motor 
score
Second 
UHDRS 
motor 
score
Valproic 
acid 
(mg/day)
Valproic 
acid serum 
level 
(µg/ml)
Mood 
stabiliza-tion
Improve-ment 
of mobility and 
manual 
dexterity
Changes in co-medication in mg
Case 1 80 72 900 30 +++ + T 100 CBZ 900 MEL 37.5 TE⇔, LO⇔ CL 25
Case 2 65 33 1200 87 - +++ R⇔
Case 3* 79 61 1800 59 + + T 100 CL 44 CLO 0.5 LEV 1000 TE⇔ CBZ 400
Case 3* 84 74 2700 43 ++ ++ T 300 TE 25 CLO 0.5 CL⇔ CBZ 400
Case 4 56 56 300 (ND) - - T⇔, TE⇔, LO⇔, OX⇔, HAL⇔
Case 5 72 66 900 73 ++ + T⇔, HAL⇔
Case 6 74 60 1050 43 +++ ++ T 150 TE 25 S 200 Q⇔
Case 7 57 50 1950 84 + +++ T3 0 0  L O1 . 5
Case 8 91 70 1350 56 ++ ++ T5 0  L O ⇔, Q⇔, MEL⇔
Clinical data and co-medication before (initial UHDRS motor score) and after (second UHDRS motor score) treatment with valproic acid. ND = no 
data; Intensity: - = no, + = mild, ++ = moderate, +++ = very good. Medication: T = Tiaprid, TE = Tetrabenazine, CBZ = Carbamazepine, CL = 
Clozapine, CLO = Clonazepam, MEL = Melperone, LO = Lorazepam, R = Rilutek, LEV = Levetiracetam, OX = Oxazepam, HAL = Haloperidol, S = 
Sulpride, Q = Quetiapin. Signs: Increase =  , decrease =   no change = ⇔. One patient (*) was treated twice with an increased dose of valproic 
acid within a 4 year period, see text.
⇓ ⇓ ⇓ ⇑
⇓ ⇓ ⇓ ⇓ ⇑
⇓ ⇓ ⇓ ⇑
⇓ ⇓ ⇓
⇓ ⇓
⇓
⇑ ⇓
Table 1: Clinical characteristics of the patients
Patient Sex CAG AO Motoric AO Psychic Duration TFC IS % Rigidity Swallowing 
problems
Case 1 M 22/46 28 22 11 2 20 ++ +++
Case 2 F 20/54 37 ND 6 5 70 + -
Case 3* M 17/48 23 23 8 3 40 ++ ++
Case 3* M 17/48 23 23 12 2 30 ++ +++
Case 4 M 19/48 33 ND 11 4 40 +++ ++
C a s e  5M 1 7 / 4 3 5 0 4 56 34 0 + + + +
Case 6 F 25/52 31 ND 10 3 40 ++ ++
C a s e  7 F 1 7 / 5 0 2 8 2 67 67 0+ -
Case 8 M 17/50 30 30 11 3 30 +++ +++
Clinical characteristics of the patients. AO = age of onset, TFC = Total functional capacity (UHDRS), IS = Independence score (UHDRS), CAG = 
CAG-ranges (low/high); Intensity: - = none, + = mild, ++ = moderate, +++ = severe. ND = no data. One patient (*) was treated twice with an 
increased dose of valproic acid within a 4 year period, see text.BMC Neurology 2006, 6:11 http://www.biomedcentral.com/1471-2377/6/11
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adult onset HD. Oral administration of clonazepam was
temporarily effective for myoclonus [16].
Furthermore, valproic acid has also been reported to be
effective as a mood stabilizer in HD [17].
We herein describe eight adult HD patients suffering from
severe action myoclonus or myoclonic hyperkinesia lead-
ing to physical disability. All patients were treated with
valproic acid. To our knowledge, this is the largest group
of patients exhibiting this rare feature to be reported thus
far.
Methods
About 90% of 600 HD patients investigated in our center
during the last 10 years showed symptoms of chorea,
about 60% suffered from choreatic movements as the
main somatic symptom. Eight patients suffered from
myoclonus as the main clinical symptom and were treated
with valproic acid. Patients were scored by Unified Hunt-
ington's Disease Rating Scale (UHDRS) motor score
before and after treatment with valproic acid [18,19].
Informed consent was obtained from each patient or the
legal guardian. Two patients agreed to be videotaped
before and after treatment with valproic acid. One patient
was capable of performing a handwriting test before and
after treatment with valproic acid. Peg insertion was per-
formed during treatment in order to evaluate executive
dysfunction and motor impairment, if possible [20,21].
All patients had been genetically tested and were sympto-
matic for HD with choreatic hyperkinesia. Additionally,
all patients showed signs of akinesia and rigidity, most of
them also suffered from dysphagia. Myoclonus, however,
was the predominant clinical symptom. All patients dem-
onstrated a worsening of myoclonus during action, some
did also present severe myoclonic hyperkinesias at rest
(case 1, 3, 6 and 7). All patients presented a multifocal
positive myoclonus. In one patient (case 3) a stimulus
sensitive myoclonus was observed, but movement also
occurred while active. No additional electrophysiological
studies were performed. One patient (case 3) had been
treated with valproic acid due to seizures before first inves-
tigation (1050 mg/per day, serum level: 31 µg/ml) but the
dose had to be increased during treatment. The same
patient was readmitted 4 years later because of worsening
of the symptoms and was treated again by increasing the
valproic acid dosage (initial dose 1800 mg, serum level:
Case 2 handwriting test with 900 mg vaproic acid treatment Figure 2
Case 2 handwriting test with 900 mg vaproic acid treatment.
Case 2 handwriting test without vaproic acid treatment Figure 1
Case 2 handwriting test without vaproic acid treatment.
Case 2 handwriting test with 1200 mg vaproic acid treatment Figure 3
Case 2 handwriting test with 1200 mg vaproic acid treat-
ment.BMC Neurology 2006, 6:11 http://www.biomedcentral.com/1471-2377/6/11
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37 µg/ml). Characteristics of all patients are described in
table 1.
Results
In seven patients myoclonic hyperkinesias and, therefore,
UHDRS scores improved in a dose-dependent manner
(see table 2). Initial mean UHDRS motor score was 73.1
(± 11.9), after treatment mean UHDRS motor score was
60.2 (± 12.8) for all patients (p = 0.042; t-test; data
showed a normal distribution according to the Kol-
mogorow-Smirnow test) due to an improvement in over-
all motor function. In three of these patients
antidopaminergic medication could be markedly reduced
(case 3, 6 and 7), in the remaining patients antidopamin-
ergic treatment was basically unchanged (table 2). Espe-
cially in case 1 and 3, swallowing improved. One patient
with a daily dose of only 300 mg valproate (case 4) did
not improve. Changes in co-medication during treatment
are presented in table 2.
In five cases a remarkable mood-stabilizing effect of valp-
roic acid could be observed. In case 2 myoclonic hyperki-
nesia improved very much due to treatment with valproic
acid. Especially mobility and manual dexterity were
improved. This is also illustrated by handwriting tests (see
picture 1 without, picture 2 with 900 mg, picture 3 with
1200 mg valproic acid). Initially and after treatment with
600 mg valproic acid, the above-mentioned patient was
not able to perform peg insertion. After treatment with
1200 mg valproic acid peg insertion was possible, how-
ever strongly impaired (319 s right hand, 481 s left hand).
Videotapes were performed before and after treatment
with valproic acid (video 1 [see Additional file 1] without
and video 2 [see Additional file 2] with 900 mg valproic
acid for case 1, video 3 [see Additional file 3] without and
video 4 [see Additional file 4] with 1950 mg valproic acid
for case 7). No relevant side effects were observed.
Discussion
Due to specific degeneration of striatal neurons even HD-
patients with hyperkinesia may develop extrapyramidal
side effects during antidopaminergic therapy. Moreover,
not only hyperkinetic involuntary movements but also
bradykinesia has been increasingly recognized as one of
the key symptoms also in early stages of the disease in
non-juvenile HD-patients [22-24]. Therefore, anti-
dopaminergic medication often leads to a worsening of
swallowing problems and gait disturbances.
In a subgroup of HD patients suffering from myoclonic
hyperkinesia, valproic acid may be a possible alternative
treatment. Valproic acid seems to be more efficient than
antidopaminergics in these patients. It has no side effects
on the extrapyramidal system as opposed to neuroleptics.
In some of our cases, reduction of antidopaminergic med-
ication caused an improvement of bradykinesia and swal-
lowing.
The effects of valproic acid seem to be dose-dependent as
demonstrated in cases 2 and 3. In case 2, handwriting tests
show a remarkable improvement after an increase of dos-
age (see pictures 1–3). Because of worsening of symp-
toms, one patient (listed as case 3) was treated twice
within a 4 year period. An improvement of symptoms
could be reached each time after increasing the dosage of
valproic acid; this might be a further indication of dose-
dependent effects. Only one patient (case 4) receiving a
daily dose of only 300 mg valproic acid did not improve.
This might be due to insufficient dosage. For all other
patients the reduction of disabling myoclonus led to a sig-
nificant improvement in daily life activity.
Almost all patients developed initial HD symptoms early
in life (AO 23 years up to 33 years) but none of them was
a juvenile HD patient with characteristic akinesia and
rigidity. Myoclonus appeared 6 to 12 years after AO of first
symptoms of the disease in all patients. Almost all
patients had an expanded CAG range between 45 and 50.
It appears that a subgroup of patients with predominant
myoclonus exists between those with typical choreatic
movements and those with the juvenile akinetic-rigid var-
iant.
As Carella et al. postulated, the gamma-aminobutyric acid
(GABA) system might be involved in the pathophysiology
of myoclonus in HD [11]. Earlier animal models with
stereotaxic injection of kainic acid into rat striatum pro-
duced neuronal degeneration and neurochemical altera-
tions resembling HD [25]. Since then, it was assumed that
correcting the deficiency in gamma-aminobutyric acid
(GABA), may be of therapeutic value.
The postulated mechanisms for myoclonus in HD have
differed in literature [26]. Neurophysiological investiga-
tions in most earlier studies, documented generalised and
multifocal action myoclonus of cortical origin. In some
cases, myoclonus was strikingly stimulus sensitive [13].
Myoclonus, as recorded by surface electromyography con-
sisted of 40–60 ms-synchronous semirhythmic bursts.
The cortical component of somatosensory evoked poten-
tial was enlarged in some cases, representing a cortical
myoclonus [1,26]. Since additional electrophysiological
studies in our cases were not performed we can only spec-
ulate about a presumed cortical origin of myoclonus fol-
lowing literature and our clinical impression.
Furthermore, there are some reports suggesting a neuro-
protective role of valproic acid, acting as a histone
deacetylase-Inhibitor [27-36]. Thus, valproic acid seemsBMC Neurology 2006, 6:11 http://www.biomedcentral.com/1471-2377/6/11
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to be a promising candidate for a new approach to treat-
ing Huntington's Disease.
Conclusion
In the rare subgroup of HD patients suffering from myo-
clonic hyperkinesia, valproic acid is a possible alternative
treatment.
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